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Introduction
Short-chain  L-3-hydroxyacyl-CoA dehydrogenase
(SCHAD) catalyzes the penultimate reaction in the
mitochondrial fatty acid oxidation spiral, the NAD+-
dependent conversion of L-3-hydroxyacyl-CoA to 
3-ketoacyl-CoA. The cDNA and genomic sequences for
human SCHAD have been elucidated (1, 2). Northern
blot analysis of SCHAD mRNA revealed a single tran-
script; expression was highest in skeletal and cardiac
muscle but also present in liver, kidney, and pancreas
(1). Earlier work had shown that the islets of Langer-
hans contain high SCHAD activity (3, 4). This suggests
that the enzyme and the regulation of fat oxidation
may have an important function in the β cell.
Deficiency of a mitochondrial fatty acid oxidation
enzyme typically produces hypoketotic hypoglycemia;
some defects also produce hepatomegaly and skeletal
and cardiac myopathy (5). Tein et al. reported reduced
SCHAD activity in muscle but not fibroblasts of a
patient with recurrent myoglobinuria, hypoketotic
hypoglycemia, and cardiomyopathy (6). Bennett et al.
described reduced SCHAD activity in the fibroblasts of
two children with recurrent ketosis and ketotic hypo-
glycemia (7) and reduced activity in the liver but not the
muscle of three sudden infant death victims (8).To date
none of these patients with reduced SCHAD activity has
been shown to have mutations in the Schad gene (9).
One patient presenting with fulminant hepatic failure
at 3 years was found to have G118A and C171A muta-
tions in the Schad gene (10). The SCHAD knockout
mouse dies if fasted for 10 hours, whereas wild-type
mice survive 24 hours (11).
Apart from fatty acid oxidation defects (FAODs), the
main cause of hypoketotic hypoglycemia in infancy is
hyperinsulinism (HI). Unlike patients with FAOD, at the
time of hypoglycemia, infants with HI have a raised plas-
ma insulin and C-peptide, a low plasma concentration of
nonesterified fatty acids (NEFAs), and a normal NEFA/D-
3-hydroxybutyrate ratio. The patient described below had
clear evidence of elevated plasma insulin and C-peptide
when she was hypoglycemic. However, on another occa-
sion, the NEFA/D-3-hydroxybutyrate ratio was at the
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A female infant of nonconsanguineous Indian parents presented at 4 months with a hypoglycemic con-
vulsion. Further episodes of hypoketotic hypoglycemia were associated with inappropriately elevated
plasma insulin concentrations. However, unlike other children with hyperinsulinism, this patient had
a persistently elevated blood spot hydroxybutyrylcarnitine concentration when fed, as well as when fast-
ed. Measurement of the activity of L-3-hydroxyacyl-CoA dehydrogenase in cultured skin fibroblasts with
acetoacetyl-CoA substrate showed reduced activity. In fibroblast mitochondria, the activity was less than
5% that of controls. Sequencing of the short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD)
genomic DNA from the fibroblasts showed a homozygous mutation (C773T) changing proline to
leucine at amino acid 258. Analysis of blood from the parents showed they were heterozygous for this
mutation. Western blot studies showed undetectable levels of immunoreactive SCHAD protein in the
child’s fibroblasts. Expression studies showed that the P258L enzyme had no catalytic activity. We con-
clude that C773T is a disease-causing SCHAD mutation. This is the first defect in fatty acid β-oxidation
that has been associated with hyperinsulinism andraises interesting questions about the ways in which
changes in fatty acid and ketone body metabolism modulate insulin secretion by the β cell. The patient’s
hyperinsulinism was easily controlled with diazoxide and chlorothiazide.
J. Clin. Invest. 108:457–465 (2001). DOI:10.1172/JCI200111294.upper limit of normal, which led to an examination of the
blood acylcarnitine profile for evidence of an FAOD. This
led to the discovery of SCHAD deficiency.
HI can be caused by gain-of-function mutations of
glucokinase and glutamate dehydrogenase and defects
in the SUR1 or KIR6.2 subunits of the KATP channel in
the β  cell membrane (12). In these disorders, the
pathogenesis of HI can be explained using a simple
model of β cell signaling: Increased β cell glucose
metabolism leads to increased ATP production from
acetyl-CoA and a rise in the ATP/ADP ratio. This clos-
es KATP channels, depolarizing the cell membrane and
causing calcium influx through voltage-gated chan-
nels, which finally triggers insulin secretion (12, 13).
Defects causing HI increase ATP production by
increasing glucose or glutamate metabolism, or they
cause permanent depolarization. The occurrence of HI
in a patient with an FAOD is difficult to explain using
this model. Our findings are therefore discussed by
reference to the Prentki two-pathway model of β cell
signaling (14). This takes account of the fact that a
shift from fatty acid oxidation to esterification is a key
event in the β cell’s response to glucose. It also recog-
nizes that it is possible to demonstrate the presence of
a KATP channel–independent mechanism that aug-
ments the β cell’s secretion of insulin in response to
high glucose concentrations (14–16).
Methods
The hypoglycemia screen. Investigation of hypoglycemia
in infancy entails measurement of insulin, NEFA, and
D-3-hydroxybutyrate at a time when the blood glucose
is less than 2.6 mM (17, 18). Typical results from our
unit are shown in Table 1. HI is diagnosed on the basis
of plasma insulin greater than or equal to 3 mU/l at the
time of hypoglycemia; in seven recent cases, the range
was 5.7–53 mU/l. In HI the plasma NEFA concentra-
tion at the time of hypoglycemia is low (<0.7 mM),
whereas in fasted children who are not hypoglycemic,
the plasma NEFA concentration is greater than 0.9
mM, and, in FAOD and ketotic hypoglycemia, the plas-
ma NEFA concentration at the time of hypoglycemia is
greater than 1.4 mM. The blood concentration of D-3-
hydroxybutyrate at the time of hypoglycemia is less
than 1.4 mM in FAOD and less than 0.4 mM in HI.
Case report. FS is the second child of nonconsan-
guineous Indian parents. She was born at 38 weeks’
gestation, weighing 3.2 kg. She fed poorly from birth.
At 4 months, she had a grand mal convulsion and her
blood glucose level was 1.4 mM. Further investigations
showed that there were no ketones in her urine after an
episode of hypoglycemia and that she had HI (1.3 mM
blood glucose, 134 pmol/l (18 mU/l) simultaneous
plasma insulin, and 108 pmol/l C-peptide), with nor-
mal serum cortisol (381 nmol/l). She was given fre-
quent feeds containing glucose polymer, and her blood
glucose remained at 3.0–4.5 mM. However, she had two
further convulsions at home; on one occasion her
plasma glucose was 2.9 mM and insulin 83 pmol/l (11
mU/l) on arrival in hospital. Nighttime hypoglycemia
was managed by the use of uncooked cornstarch.
At 14 months, FS was referred to Great Ormond
Street Hospital. She showed evidence of HI, but this
was intermittent and unpredictable (Table 1). She
required a glucose intake of 8 mg/kg/min to maintain
blood glucose levels greater than 2.6 mM; a require-
ment of more than 6 mg/kg/min indicates HI (18). On
one occasion, she tolerated an 18-hour fast without
becoming hypoglycemic. On another occasion, after
only a 4-hour fast, she had a blood glucose level of 2.5
mM, insulin level of 668 pmol/l (89 mU/l), NEFA of
0.17 mM, and D-3-hydroxybutyrate of 0.01 mM. These
results were consistent with HI; however, on other occa-
sions, hypoglycemia occurred without HI. For example,
3 hours after a glucagon provocation (19), she had a
blood glucose of 2.1 mM with an insulin level of 1.0
mU/l, NEFA of 2.37 mM, and D-3-hydroxybutyrate of
1.38 mM (NEFA/D-3-hydroxybutyrate ratio at upper
end of normal range; ref. 17). Urine organic acid analy-
sis showed mildly raised 3-hydroxybutyrate, 3-hydroxy-
glutarate, and 3,4-dihydroxybutyrate.
FS was readmitted at 19 months because of recurrent
hypoglycemia with fits. She had frequent episodes of
hypoglycemia in the hospital. Once when the blood
glucose was 2.3 mM, the plasma insulin was 2.6 mU/l,
demonstrating a failure to switch off insulin release
completely. In view of the high normal NEFA/D-3-
hydroxybutyrate ratio recorded on one occasion, a
series of blood spot acylcarnitine analyses were under-
taken; these all showed raised hydroxybutyrylcarnitine.
In view of the hypoglycemic screens suggesting HI, FS
was commenced on diazoxide (5 mg/kg/d) and
chlorothiazide (7 mg/kg/d). This led to an improve-
ment in the blood glucose profile, and she could toler-
ate a 24-hour fast without becoming hypoglycemic.
Feeding remained a major problem, eventually requir-
ing a gastrostomy. She was discharged on diazoxide and
chlorothiazide. Her glucose control has remained good
with no further seizures or episodes of hypoglycemia.
Acylcarnitine analysis by electrospray ionization tandem
mass spectrometry. Blood spots were obtained from FS 
1-2 hours after a feed and at times of hypoglycemia. The
acylcarnitine profiles were compared with those
obtained in random blood spots from 33 normal
infants and children and in fasting blood spots from 14
children who were ketotic at the end of a diagnostic fast
but whose metabolite and endocrine profile was within
our normal range (17). They were also compared with
fasting and nonfasting blood spot acylcarnitine profiles
from six children with HI.
For analysis of free carnitine and acylcarnitines (as
butyl esters), 4.7-mm discs were punched from the
Guthrie Card (filter paper containing the blood spot)
into 96-well polystyrene microtiter plates. The internal
standards added to each sample were D9-carnitine and
D3 -acetyl, -propionyl, -octanoyl, and -palmitoyl car-
nitines. The carnitine species in a blood spot were eluted
by sonication with 85% methanol and transferred in
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microtiter plate. The dried sample was dissolved in
butanolic HCl and heated to 45°C for 60 minutes. The
butanol/HCl was removed with a stream of oxygen-free
nitrogen, and the dried sample was reconstituted in 150
µl of 1:1 acetonitrile/water. A 7-µl injection was made
into the electrospray ionization source of a Micromass
Quattro LC mass spectrometer (Micromass Ltd., Altrin-
cham, United Kingdom). For analysis of butylated car-
nitine species (0.8 min), the first quadrupole was set to
scan from mass/charge ratio (m/z) 200 to 600, and the
second mass filter was set to detect fragment ions of m/z
85. Fragment ions of this mass/charge ratio are pro-
duced on collision-induced dissociation of the butyl
esters of free carnitine and all acylcarnitines; they are
believed to originate from the carboxyl group of the car-
nitine plus carbons 2, 3, and 4.
The size of the hydroxybutyrylcarnitine peak was com-
pared with that of the D3-octanoylcarnitine internal
standard (added in an amount equivalent to a concen-
tration of 10 µM in the blood). The blood spot acetyl-
carnitine concentration was measured by comparison of
the peak size with that of the D3-acetylcarnitine stan-
dard. Differences between blood spot acetylcarnitine
concentrations in FS and ketotic and hyperinsulinemic
children were evaluated using the ttest.
Measurement of 3-hydroxyacyl-CoA dehydrogenase activi-
ty. Short-, medium-, long-chain and 2-methyl-short-
chain 3-hydroxyacyl-CoA dehydrogenase activities
were measured in fibroblasts essentially as described
by Jackson et al. (20). Fibroblast pellets were resus-
pended in 25 mM phosphate, 0.2 mM EDTA, and 0.2%
vol/vol Triton X-100 (pH 8.0) and incubated on ice for
30 minutes. After centrifugation (11,600 gav for 10
minutes), 3-hydroxyacyl-CoA dehydrogenase activity
was measured in the supernatant in the reverse direc-
tion by following the disappearance of NADH at 340
nm. The reaction medium consisted of 0.1 M potassi-
um phosphate (pH 7.0)/0.1 mg/ml NADH/0.3 mg/ml
BSA (fatty acid free), plus 40 µM ketoacyl-CoA sub-
strate (short chain, acetoacetyl-CoA [Sigma Chemical
Company, Poole, United Kingdom]; medium-chain, 
3-ketooctanoyl-CoA; long-chain, 3-ketohexadecanoyl-
CoA the latter of two substrates being synthesized as
described previously [ref. 21]; and 2-methyl-3-hydrox-
yacyl-CoA dehydrogenase, 2-methyl-acetoacetyl-CoA).
2-Methyl-acetoacetyl-CoA was synthesized from tiglyl-
CoA (Sigma) by the sequential actions of crotonase
(Sigma) and pig heart 3-hydroxyacyl-CoA dehydroge-
nase (Sigma) and purified by HPLC. Citrate synthase
activity (22) and protein concentration (23) were also
measured on the fibroblast supernatant.
Isolation of mitochondria. Suspensions enriched in mito-
chondria were prepared from fibroblasts of the patient
and a control as described by Hoogeboom (24). Activities
of SCHAD and LCHAD were measured in homogenates
of freshly prepared mitochondrial suspensions.
Western blotting. Proteins from fibroblast supernatants
prepared as above were separated by SDS-PAGE on a
12% gel, electroblotted overnight, and detected by West-
ern blotting using a rabbit antibody against pig heart
SCHAD (from D M Turnbull) and a standard ECL+
protocol (Amersham Pharmacia Biotech Little Chal-
font, Bucks, UK). Antibody dilutions were 1:1,000 (pri-
mary) and 1:10,000 (secondary). Additional standards
of pig heart (Sigma) and bovine liver (Sigma) SCHAD,
and rat liver mitochondria were run in parallel.
Immunoprecipitation of SCHAD. Anti-SCHAD antibody
was conjugated to Protein A-acrylic beads (250 µm;
Sigma) according to the manufacturers’ instructions.
A total of 25 µl of fibroblast supernatant was incubat-
ed with 40 µl anti-SCHAD beads for 2 hours at 4°C,
after which 1 ml of SCHAD assay buffer was added, the
beads removed by centrifugation (11,600 gav for 2 min-
utes), and HAD assay carried out using acetoacetyl-CoA
as described above.
DNA sequence analysis. DNA was isolated from
fibroblasts from FS and a control. Exon-specific PCR-
amplification of Schad sequences was performed with
the appropriate primer pair for each exon (Table 2;
optimal experimental conditions for primer pairs
available on request). PCR products were analyzed on
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Table 1
Results hypoglycemia screens/diagnostic fasts
Plasma insulin Plasma NEFA Blood D-3-OH-butyrate
(mU/l) (mM) (mM)
FSA 0, 2.6, 18, 89 0.17, 2.37 0.01, 1.38
HI (n = 5) 5.7, 7.5, 12, 21,53 0, 0.26, 0.27, 0.62, 0.63 0 (n = 4), 0.38
MCAD (n = 3) 0 (n = 3) 3.04, 3.40, 4.11 0.7, 1.23, 1.34
VLCAD (n = 1) 1.4 2.46 0.22
LCHAD (n = 2) 0 (n = 2) 1.43, 1.71 0.08, 0.2
KH (n = 5) 0 (n = 5) 2.39, 2.5, 2.69, 3.12, 3.38 1.49, 1.76, 1.89, 3.09, 5.04
Normal (fasted but not 1.1, 1.2, 1.4, 1.9, 2.1, 2.2, 5.0 0.95, 1.22, 1.33, 1.38, 1.57, 1.7, 2.34 0.26, 0.7, 1.14, 1.93, 2.07, 3.24, 5.04
hypoglycemic; n = 7)
Blood/plasma concentrations of insulin, NEFA, and D-3-hydroxybutyrate at times of hypoglycemia (blood glucose <2.6 mM) in patient FS and age-matched
children with hypoglycemia due to hyperinsulinism [HI], fatty acid oxidation defects (medium chain acyl-CoA dehydrogenase deficiency [MCAD], very long
chain acyl-CoA dehydrogenase deficiency [VLCAD], long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency [LCHAD]), and ketotic hypoglycemia [KH]. Also
shown are values for insulin, NEFA, and D-3-hydroxybutyrate for normal children who were not hypoglycemic at the end of a diagnostic fast (17). A value of
zero indicates a concentration below the limit of detection of the assay. ASee Methods for a description of the experimental conditions corresponding to the
values reported for patient FS.an ABI prism 377 DNA sequencer using the ABI Prism
dRhodamine Terminator Cycle Sequencing Ready
Reaction kit (PE Applied Biosystems, Foster City, Cal-
ifornia, USA). Sequence data were analyzed with the
Lasergene 99 software program (DNA STAR Inc.,
Madison, Wisconsin, USA).
Restriction fragment length analysis. Genomic DNA of
FS, her parents, and 100 controls (50 ethnically
matched) was subjected to PCR amplification using
exon 7–specific SCHAD primers (Table 2). The PCR
products were exposed to Apa1 Roche Molecular Bio-
chemical, Mannheim, Germany) for 2 hours and ana-
lyzed on a 2% agarose gel.
In vitro expression of SCHAD. Total RNA was isolated
from fibroblasts of FS and a control. RNA (10 µg) was
reverse transcribed using oligo(dT) and MMLV RT
(Invitrogen Life Technologies Corporation, Groningen,
Netherlards). The complete coding sequence of SCHAD,
81 nucleotides of the 5′UTR, and 33 nucleotides of the
3′UTR were amplified using primers CAGAGTCTG-
GCTTTCCGCGG and AGGTGTTCTTCTCAGAGCCG, and
Advantage cDNA polymerase mix (CLONTECH Labo-
ratories Inc., Palo Alto, California, USA) for 30 cycles.
The PCR products were applied to a 1% agarose gel, and
the band with the appropriate size was excised, eluted,
and reamplified with the same primers for 30 cycles.
Amplified cDNAs were cloned in pCR2.1 (Invitrogen),
and individual clones were sequenced as described earli-
er. The faultless wild-type SCHAD sequence was sub-
cloned in pBluescriptSK+ (Stratagene, La Jolla, Califor-
nia, USA). A SCHAD coding sequence containing the
mutation detected in patient DNA was composed of a 5′
EcoRI-BstEII fragment from the normal SCHAD coding
sequence and a 3′BstEII-EcoRI fragment from the patient
SCHAD coding sequence and subcloned in pBluescript-
SK+. To ascertain proper subcloning, the integration
sites of the inserts and the inserts of the obtained plas-
mids were resequenced completely from both sides.
Wild-type and mutant proteins were synthesized in a
reticulocyte lysate (Promega Corp., Madison, Wisconsin,
USA)by coupled in vitro transcription translation from
the T7 promoter according to the manufacturer’s
instructions. Plasmid containing no insert was used as a
control. Enzyme activity was assayed immediately after
protein expression, by measuring the
disappearance of NADH at 340 nm,
using acetoacetyl-CoA (Sigma) as a sub-
strate. Production of SCHAD protein
was analyzed by SDS-PAGE followed by
Western blotting. Proteins recognized by
the antibody were visualized by chemi-
luminescence (ECL+).
Results
Acylcarnitine analysis (electrospray ioniza-
tion tandem mass spectrometry). A “pre-
cursors of m/z 85” scan obtained on
analysis of the patient’s blood spot is
shown in Figure 1. The spectrum shows
a clear peak of m/zratio of 304, indicating the presence
of hydroxybutyrylcarnitine (butyl ester) or an isomeric
compound. The concentration was always more than
0.8  µM, even in nonfasting samples (Table 3). An
hydroxybutyrylcarnitine peak could be seen in some
normal controls, in some of the normal children who
were ketotic at the end of a diagnostic fast, and in some
of the hyperinsulinemic children who had hypoketotic
hypoglycemia at the end of a fast. However, none of
these children had a blood hydroxybutyrylcarnitine
concentration greater than 0.5 µM (Table 3). The mean
(± 1 SD) acetylcarnitine concentration in blood spots
from FS was 27.74 ± 9.8 µM, which was significantly
higher (P < 0.0005) than the concentration in blood
from normal controls (16.54 ± 3.34) but not signifi-
cantly different from the blood spot acetylcarnitine
concentrations in other hyperinsulinemic children
(fasting, hypoglycemic = 26.7±9.7; nonfasting, normo-
glycemic = 26.4 ±9.7). Other carnitine species in blood
spots from FS were normal apart from occasional mild
elevation of C3, C4, and C18 species (≤ 2 of 16 determi-
nations outside normal range; NS): free carnitine 47–68
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Table 2
Sequences of primer pairs used to amplify exon 1 to exon 8 of Schad
Exon 1 CCGGGTCTCCTCGCTGTC GCCAGAGCTTCACCTCAG
Exon 2 GTTGACTTATCATATGTTCACTCGG CCCATTGCCCTGCAAATGTAAAGC
Exon 3  GATAATTTCCAGTGAGCCCG GAGAAGATTGTCCAGAGG
Exon 4 CATCCAAGAGTCATGCTG AAAGCAGGACTGAGAGAGC
Exon 5 CTGAAGTTGCTTGCTGAC CAGGAACAAGTCAGGGTCC
Exon 6 GGGCAATTTGGTGACTTC CTAGAGACACTGAGAATTCCAGA
Exon 7 GTGATAGGGAGAATTCAAGG GCAGGACTTTGGAAGGTC
Exon 8 CCAGCACTTCATCCTGAGTTCT GTAGGGCAAGACTCAAAGC
See Vredendaal et al., 1998 (2); sequences derived from AF026856-67, NM_005327, and unpub-
lished sequences. The forward primers are presented in the middle column, the reverse primers
in the right column.
Figure 1
Analysis of butyl esters of carnitine and acylcarnitine species in a
blood spot from FS. Peak identities are: m/z 218, free carnitine;
227, D9-carnitine; 260, acetyl-carnitine; 263, D3-acetylcarnitine;
277, D3-propionylcarnitine; 304, hydroxybutyrylcarnitine; 347, 
D3-octanoylcarnitine; 456, palmitoylcarnitine ; 459, D3-palmitoyl-
carnitine; and 482, oleoylcarnitine.(normal range 28.5–109); C3, 0.62–1.64 (<1.27); C4,
0.22–0.74 (<0.72); C5, 0.24–0.58 (<1.22); C6, 0–0.12
(<0.48); C8, 0–0.24 (<0.72); C14:1, 0.04–0.28 (<0.55); C16,
1.04–1.64 (<8.43); C18:2, 0.20–0.82 (<0.64); C18:1,
0.96–2.64 (<2.36); and C18, 0.04– 0.98 (<0.86).
Activity of L-3-hydroxyacyl-CoA dehydrogenases. The short-
chain HAD activity measured in fibroblasts from FS was
significantly lower than that in control fibroblasts
whether the activity was expressed per mg protein, as a
ratio to LCHAD, or as a ratio to citrate synthase (Table
4). Residual activity in fibroblasts from FS was 35–40%
the activity of the controls. Long-chain HAD activity in
fibroblasts from the known LCHAD-deficient patient
was significantly reduced, but long-chain HAD activity
in fibroblasts from FS was not significantly different
from that in controls. There was no significant differ-
ence in medium-chain HAD activity between FS and
controls. When SCHAD and LCHAD activity were
measured in a mitochondrial fraction from fibroblasts,
the values for FS were 4% and 3% in two separate exper-
iments (SCHAD) and 142% (LCHAD) of the simultane-
ously assayed control fibroblast mitochondrial fraction.
Western blotting. Western blotting of fibroblasts from
FS indicated a complete lack of SCHAD immunoreac-
tive protein, whereas SCHAD was readily detectable in
both control fibroblasts and fibroblasts from an
LCHAD-deficient patient (Figure 2).
DNA analysis. Sequence analysis of
DNA fragments (together comprising
the complete coding sequence of
SCHAD), amplified from genomic DNA
of patient FS, revealed a homozygous
C→Tpoint mutation in exon 7 of Schad.
No other mutations were detected. The
mutated nucleotide corresponds to
nucleotide (nt) 773 of the coding
sequence (taking the A of the translation
start codon as nt 1). The C773T point
mutation abrogates an ApaI restriction
site present in the normal Schad
sequence. Amplification of DNA frag-
ments containing nt 773 from patient
DNA and from DNA of the parents, fol-
lowed by ApaI digestion and analysis on an agarose gel,
confirmed that FS is homozygous and showed that her
parents are heterozygous for the C773T mutation (Fig-
ure 3). The mutation could not be detected in DNA from
200 control chromosomes. The C773T mutation leads to
replacement of Pro258 (Pro246 of the mature SCHAD
protein) by Leu. Pro258 is completely conserved in
SCHAD sequences from different species (Figure 4).
In vitro expression of SCHAD. To assess theeffect of the
P258L substitution on the activity of the protein, the
wild-type and the mutated protein were synthesized in
vitro from plasmids containing the wild-type SCHAD
coding sequence and the SCHAD coding sequence har-
boring the C773T point mutation, respectively. The
absence of amplification artifacts in the wild-type con-
struct and of mutations other than the C773T point
mutation in the patient construct was ascertained by
sequencing of the SCHAD expression plasmids in two
directions. Expression of the wild-type SCHAD protein
in a reticulocyte lysate system yielded a protein with an
apparent molecular mass of approximately 35 kDa,
which is in agreement with the calculated molecular mass
of the wild-type protein of 34.3 kDa. The in vitro
expressed mutated protein reacted strongly with the anti-
SCHAD antibody and had an apparent molecular mass
0.5 kDa less than that of the wild-type protein (Figure 5).
Immunoblot analysis showed that comparable amounts
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Table 3
Comparison of concentrations of hydroxybutyrylcarnitine in blood
Subjects Hydroxybutyrylcarnitine  concentration  (µM)
Mean Range
FS (samples = 16) 1.78 0.92–3.04
Normal ketosis (n = 14) 0.20 0.08–0.50
(Fasting, mean D-3-OH-butyrate = 1.64 mmol/l)
Non-fasting controls (n = 33) 0.096 0.0–0.36
Hyperinsulinemic hypoglycemia (n = 6) 0.18 0.06–0.36
(Fasting, blood glucose <2.5 mM, 
D-3-hydroxybutyrate <0.05 mM)
The concentration of hydroxybutyrylcarnitine (m/z 304) in (a) blood spots from FS; (b) blood spots
from children with ketosis at the end of a (normal) diagnostic fast; (c) blood spots from non-fast-
ing controls; and (d) blood spots from hyperinsulinemic children who had hypoketotic hypo-
glycemia at the end of a diagnostic fast.
Table 4
Activities of 3-hydroxyacyl-CoA dehydrogenases in the patient and in controls
C4 HAD  C8 HAD  C16 HAD C4 HAD/ C4 HAD/citrate  C8 HAD/citrate  C16 HAD/citrate
(mU/mg protein) (mU/mg protein) (mU/mg protein) C16 HAD ratio synthase (U/UCS) synthase (U/UCS) synthase (U/UCS)
Controls 0.66 ± 0.15 2.28 ± 0.46 1.22 ± 0.26 0.54 ± 0.07 0.14 ± 0.04 0.36 ± 0.03 0.26 ± 0.06
(n = 7)
FS (patient) 0.26 ± 0.16B 1.91 ± 0.49 0.97 ± 0.15 0.16 ± 0.13A 0.05 ± 0.02A 0.34 ± 0.07 0.21 ± 0.05
(n = 6)
SB (known  0.56 ± 0.12 0.66 0.42 ± 0.15C 1.38 ± 0.21C 0.13 ± 0.02 0.27 0.09 ± 0.00C
LCHAD-deficient, 
n = 3)
Activity in FS  39% 84% 80% 30% 36% 94% 77%
as % of controls
Activities of short-chain (C4 HAD), medium-chain (C8 HAD), and long-chain (C16 HAD) 3-hydroxyacyl-CoA dehydrogenase expressed as HAD activity per milligram
of protein; C4/C16 HAD ratio; and HAD/citrate synthase ratio in control fibroblasts, fibroblasts from patient FS, and from SB, a known LCHAD-deficient patient.
1 U = 1 µmol/min. UCS = units of citrate synthase activity in µmol/min. Significantly different from controls (Student’s t test): AP < 0.001, BP < 0.01, CP < 0.05.of protein were obtained for the wild-type and mutated
SCHAD protein, whereas the vector alone did not yield a
positive band of similar molecular mass (Figure 5).
SCHAD activity was assayed in three separate experi-
ments (Figure 5). The wild-type SCHAD exhibited a dis-
tinct but variable activity, whereas the mutated SCHAD
did not yield activity above background in all experiments
performed, indicating that the P258L substitution abol-
ishes enzyme activity of in vitro expressed SCHAD.
Discussion
FS suffered frequent, severe hypoglycemia. Three hypo-
glycemia screens indicated definite HI (blood glucose
<2.6 mM, plasma insulin >3 mU/l; ref. 20) as did the
glucose requirement of 8 mg/kg/min (although many
hyperinsulinemic infants require more than 15
mg/kg/min; ref. 18). The episode of hypoglycemia that
followed the glucagon test was not attributable to HI
but rather suggested impaired fatty acid oxidation.
(The pathogenesis of hypoglycemia in FAOD is proba-
bly multifactorial. NEFA cannot be used and blood
concentrations of ketone bodies are low, so glucose uti-
lization is increased; however, in addition, gluconeoge-
nesis is probably impaired because acetyl-CoA concen-
trations in the liver are low.) Treatment with diazoxide
and chlorothiazide led to a dramatic improvement in
glucose homeostasis, providing further evidence that
HI was the main cause of hypoglycemia.
The possibility of impaired fatty acid oxidation was
investigated by examination of the blood acylcarnitine
profile. All samples showed an elevated concentration of
a carnitine species with an m/z ratio of 304. This could
be due to a hydroxybutyryl-carnitine or isomeric carni-
tine species. A similar peak has been reported in children
with ketosis, so we had to prove that FS had levels of this
compound that were higher than those seen in ketosis
even when FS had been fed and was not ketotic (Table 3).
A number of identities for the “hydroxybutyrylcarnitine”
were considered along with theories as to why it might
be accumulating. The hypotheses were accumulation of
(a) L-3-hydroxybutyrylcarnitine due to SCHAD deficien-
cy; (b) 3-hydroxyisobutyrylcarnitine due to 3-hydroxy-
isobutyryl-CoA deacylase deficiency; or (c) D-3-hydroxy-
butyrylcarnitine due to a ketone body utilization defect
(KBUD). The SCHAD hypothesis was consistent with a
NEFA/D-3-hydroxybutyrate ratio toward the upper limit
of normal. The deacylase hypothesis seemed unlikely
upon comparison of FS with the case described previ-
ously (25). Plasma concentrations of D-3-hydroxybu-
tyrate did not suggest a KBUD.
Rather than prove that the compound in the blood
was L-3-hydroxybutyrylcarnitine and that the urine con-
tained excess L-3-hydroxybutyrate (which is indistin-
guishable from D-3-hydroxybutyrate on simple organic
acid analysis), it was decided to move directlyto an assay
of SCHAD. SCHAD is expressed in many tissues (26)
and has previously been assayed in fibroblasts. Clear evi-
dence of reduced SCHAD activity was seen in fibrob-
lasts from FS. There was no impairment in hydrogena-
tion of 3-ketooctanoyl-CoA, a medium-chain substrate,
in keeping with our organic acid and acylcarnitine
analyses but at variance with the evidence of impair-
ment in medium-chain 3-hydroxyacyl-CoA dehydroge-
nase activity in an SCHAD-knockout mouse and in
another SCHAD-deficient patient (10, 11).
There was high residual SCHAD activity in the
patient’s fibroblasts, which was surprising, as Western
blots indicated that the fibroblasts contained no
immunoreactive protein. There was no fall in residual
enzyme activity in the patient’s fibroblasts after
immunoprecipitation of residual SCHAD protein. The
residual activity could be due to several enzymes: (a) Tri-
functional protein HAD activity. This is unlikely because
462 The Journal of Clinical Investigation | August 2001 | Volume 108 | Number 3
Figure 2
Western blot analysis of SCHAD in fibroblasts. Fibroblast homogenates
(100 µg protein) were analyzed by SDS-PAGE, electroblotted, and visu-
alized by reaction with rabbit anti-SCHAD and ECL+. The results were
compared with purified pig heart SCHAD, bovine liver SCHAD, and a
rat liver mitochondrial preparation (protein loadings shown).
Figure 3
Restriction fragment length analysis of DNA fragments containing nt
773 of the SCHAD coding sequence. DNA from FS, her parents, and
controls was amplified using primers for exon 7 (Table 2). The PCR
product was analyzed on a 2% agarose gel, either untreated (lane 1)
or after exposure to ApaI for 2 hours (lanes 2–5). The C773T muta-
tion abrogates an ApaI restriction site present in the normal
sequence. ApaI digestion of the DNA fragment from controls yields
two bands of 121 and 171 nt (asterisk). Exposure of the mutated
sequence to ApaI yields a single band of 292 nt (arrow). Lane 1,
patient DNA fragment (untreated); lane 2, DNA fragment of the
father after ApaI treatment; lane 3, DNA fragment of the mother
after ApaI treatment; lane 4, DNA fragment of the patient treated
with ApaI; lane 5, DNA fragment of a control treated with ApaI. The
pattern of the DNA fragments of the parents reveals the presence of
both the normal and the mutated sequence.this enzyme has low activity toward acetoacetyl-CoA (27)
and residual SCHAD activity was detectable after
immunoprecipitation of SCHAD protein from an
LCHAD-deficient cell-line. (b) Peroxisomal L- and D-3-
hydroxyacyl-CoA dehydrogenases(28). (c) Presence of
type II 3-hydroxyacyl-CoA dehydrogenase(29) or human
brain multifunctional dehydrogenase(30) in fibroblasts.
(d) Short-chain 2-methyl-3-hydroxyacyl-CoA dehydro-
genase (31). Using 2-methylacetoacetyl-CoA as substrate,
activity of this enzyme was low (0.32 mU/mg protein in
control fibroblasts, 0.42 mU/mg in FS). Because it is only
half as active toward straight chain as toward 2-methy-
lacyl-CoA esters (31), it is unlikely, however, that this
enzyme was responsible for the residual activity.
Given that the residual activity was substantially
reduced when a mitochondrial preparation was used, it
seems likely that it was due to peroxisomal enzyme(s).
Sequencing of the Schad gene from fibroblasts
showed that FS is homozygous for a C773T mutation
that leads to a change from proline to leucine at amino
acid 258 (246 in the mature protein after cleavage of
the mitochondrial targeting sequence); the parents are
heterozygotes. Several lines of evidence indicate that
C773T is responsible for the reduction in SCHAD
activity and is a disease-causing mutation: (a) No other
difference from the wild-type sequence was detected in
the any of the eight exons of Schad from FS. (b) The
C773T mutation was not found in 200 control chro-
mosomes, including 100 from individuals with the
same ethnic background, indicating that the mutation
is not a common polymorphism. (c) As shown in Fig-
ure 4, Pro258 is part of a highly conserved amino acid
region, and the equivalent of Pro258 is present in
SCHAD of all species investigated. (d) Analysis of the
crystal structure of SCHAD reveals that Pro258 is the
starting point of one of the α-helices (α12) of the C-ter-
minal domain(32). Barycki et al. argue that the orien-
tation of these α-helices relative to one another is crit-
ical for enzyme function. Replacement of the proline at
the starting point of an α-helix by leucine is likely to
prevent normal protein folding. This could lead to
rejection by the chaperonin system (leading to destruc-
tion of the nascent protein) or to synthesis of a protein
with reduced catalytic activity.
The Western blots indicated reduced immunoreactive
SCHAD protein in fibroblasts. This suggests that the
P258L substitution alters the tertiary structure of the nas-
cent enzyme to such a degree that it is not recognized by
chaperonins and is destroyed. This phenome-
non has been described for point mutations in
short-chain acyl-CoA dehydrogenase (33).
Additional evidence that the C773T muta-
tion in the SCHAD coding sequence is
responsible for the patient’s disease is provid-
ed by the functional assay after in vitro expres-
sion of the mutated protein. We included 81
nucleotides of the 5′UTR, in addition to the
complete coding sequence, as a template for
the expression of the SCHAD protein, to
ensure protein formation starting from the translation
start site. It has been shown that absence of the
sequences upstream of the translation start codon may
lead to aberrant choice of translation start sites by the
in vitro expression system (34). The SCHAD protein
expressed from the wild-type construct had an apparent
molecular mass of the expected size. The mutated
sequence yielded a comparable amount of protein with
a slightly lower apparent molecular mass as determined
by SDS-PAGE. This is probably due to the P258L sub-
stitution The protein folding introduced by proline in
the wild-type sequence cannot be undone by denatur-
ing the protein, so the wild-type protein may exhibit a
different migration pattern in a denaturing gel than the
mutant protein. The complete absence of SCHAD activ-
ity of the in vitro synthesized protein harboring the
P258L substitution further corroborates the link
between the mutation and the patient’s disease.
The acylcarnitine profile in blood from FS was
unique with regard to the presence of more than 0.6
µM of hydroxybutyrylcarnitine. However, it was also
abnormal to the extent that the acetylcarnitine con-
centration was usually above the normal range. Com-
parison with other hyperinsulinemic children sug-
gested that elevation of blood spot acetylcarnitine is
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Figure 4
Diagram of aligned SCHAD sequences from several evolutionarily distant
species. Pro258 (in bold), which is replaced by Leu in the DNA of FS, is com-
pletely conserved in the SCHAD coding sequences from different species, includ-
ing bacteria. Human, NP_005318; Pig, AAD20939; Caenorhabditis elegans,
P41938; Clostridium acetobutylicum, AAA95971.
Figure 5
Expression of wild-type and C773T mutant SCHAD using a reticulocyte
lysate system. (a) Western blot showing no protein with vector alone,
immunoreactive SCHAD protein with an apparent molecular weight of
35 kDa with the wild-type SCHAD construct, and immunoreactive
SCHAD protein with a slightly lower apparent molecular weight with
the C773T mutant construct. (b) SCHAD enzyme activity obtained with
expression of the wild-type and C773T mutant SCHAD proteins.
Enzyme activity is equal to the nanomole substrate converted per micro-
liter of reticulocyte lysate between 10 and 30 minutes’ incubation.caused by HI rather than being a specific effect of
SCHAD deficiency. How could HI lead to an elevated
concentration of acetylcarnitine in blood? Insulin
leads to increased production of acetyl-CoA from glu-
cose in muscle and it is likely that when acetyl-CoA is
being produced by pyruvate dehydrogenase at a rate
that exceeds its removal in the Krebs cycle, it is
buffered by conversion to acetylcarnitine.
The hypoglycemia observed in FS was not typical of
a FAOD; it was not easily provoked by a prolonged fast,
but, rather, occurred in an unpredictable fashion, often
2–6 hours after a feed. On some occasions the plasma
insulin level was elevated, but on others, it was normal
and the NEFA/D-3-hydroxybutyrate ratio was at the
upper limit of normal (a supranormal value is typical
of hypoglycemia due to a FAOD). Although it is con-
ceivable that FS has two separate genetic defects, one in
the Schad gene and another causing HI, we believe it
more likely that the absence of SCHAD activity in the
β cell causes inappropriate insulin secretion; SCHAD
is abundant in the β cell (3, 4) because it fulfills an
important regulatory function.
The postulated role of lipid signaling in insulin secre-
tion is shown in Figure 6 (right); the pathway that trig-
gers secretion via the increased ATP/ADP ratio is shown
on the left (14). Fatty acids are a major energy source for
unstimulated islets. An early change caused by glucose is
a shift from fatty acids to glucose as fuel. It is proposed
that this occurs through conversion of glucose to mal-
onyl-CoA, which inhibits carnitine palmitoyl transferase
I (CPT I) and blocks the entry of long chain fatty acyl CoA
(LCFA-CoA) into the mitochondrion. Thus LCFA-CoA is
converted instead into diacylglycerol, triglycerides, fatty
acids, and acylated proteins. LCFA-CoA or the complex
lipids derived from them are potent regulators of
enzymes, ion channels, and signal-transducing effectors.
It is proposed that the complex lipids or acylated proteins
augment insulin secretion by a KATP-independent mech-
anism. Unequivocal evidence for such a lipid-linked sig-
naling mechanism is lacking, but there is experimental
evidence for a KATP-independent mechanism that aug-
ments insulin secretion in response to glucose (13–15).
What effects would FAOD in general, and SCHAD defi-
ciency in particular, have on the lipid signaling pathway?
Any defect leading to accumulation of cytosolic LCFA-
CoA and increased esterification could induce inappro-
priate insulin secretion. Accumulation of triglyceride,
particularly in liver, occurs in LCHAD deficiency, in very
long chain acyl-CoA dehydrogenase (VLCAD) deficiency,
and in medium chain acyl-CoA dehydrogenase (MCAD)
deficiency during fasting-induced decompensation (35).
However, our data do not suggest that these FAOD pro-
duce HI (Table 1). It is possible that in SCHAD deficien-
cy, accumulation of short chain acyl-CoA esters in the
mitochondrion causes insulin secretion by inhibition of
CPT I. The isoform of CPT I in the β cell is the same as
that in the liver(36). This enzyme, located in the outer
mitochondrial membrane, has one inhibition site that
faces the cytosol and is inhibited by dicarboxylic CoA
esters (physiologically by malonyl-CoA) and a second
inhibition site, facing the intermembrane space, that is
inhibited by short chain mono-carboxylic CoA esters(37).
What would be the role of inhibition of CPT I by L-3-
hydroxybutyryl-CoA? We hypothesize that it is the cell’s
ketone body–sensing mechanism. High levels of D-3-
hydroxybutyrate and acetoacetate in the blood will lead
to a rise in intramitochondrial acetoacetyl-CoA via the
ketone body utilization pathway. In a cell containing
abundant SCHAD, operation of the enzyme in the
“reverse” direction would lead to accumulation of L-3-
hydroxybutyryl-CoA. Inhibition of CPT I by L-3-hydrox-
ybutyryl-CoA would inhibit fatty acid oxidation and, in
the β cell, lead to insulin secretion. In muscle, acetoac-
etate and 3-hydroxybutyrate inhibit fatty acid oxidation
by a mechanism independent of malonyl-CoA (38).
Our patient’s hypoglycemia responded to diazoxide,
which inhibits insulin secretion by keeping KATP chan-
nels open. This does not disprove the hypothesis that HI
in SCHAD deficiency is due to stimulation of the lipid-
signaling pathway; the Prentki model suggests that large
amounts of insulin are only secreted if both the KATP
channel and the lipid-signaling pathway are activated.
There are significant differences between FS and previ-
ous putative cases of SCHAD deficiency. In contrast to
the child reported by Tein et al.(6), FS had no evidence of
skeletal or cardiac myopathy and SCHAD activity was
low in her fibroblasts. The cases reported by Bennett et al.
in 1996 (7) had a vigorous ketone response to hypo-
glycemia and medium- and long-chain 3-hydroxydicar-
boxylic acids in the urine. Neither of these features was
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Figure 6
The two postulated pathways for β cell signaling (from ref. 14). PDH,
pyruvate dehydrogenase; PC, pyruvate carboxylase; CL, citrate lyase;
CPT1, carnitine palmitoyl transferase 1; m, mitochondrial; c, cytoso-
lic; AcCoa, acetyl-CoA; LCFA-CoA, long-chain fatty acyl-CoA.present in FS. It is possible that some patients previously
reported as SCHAD deficient (6–8)were in fact deficient
in other enzymes with SCHAD activity. However, the
recently reported patient with G118A and C171A muta-
tions in the Schad gene, presented with fulminant liver
failure at 3 years (10); HI was not reported. This raises the
possibility of phenotypic variation in SCHAD deficiency.
The SCHAD-knockout mouse dies when subjected to a
10-hour fast (11); our observations suggest that this
could be due to hyperinsulinemic hypoglycemia.
We have checked acylcarnitine profiles in other chil-
dren with HI and found no further cases with a raised
hydroxybutyrylcarnitine, suggesting that SCHAD defi-
ciency is a rare cause of HI. However, cases such as this
provide important insight into normal biochemistry
and physiology. In this case, the biochemistry of the 
β cell and the physiology of insulin secretion.
In summary, we describe here a new syndrome of
hyperinsulinism and SCHAD deficiency that should be
easily recognizable by analysis of acylcarnitine species
and that responds well to treatment with diazoxide. It
provides, to our knowledge, the first “experiment of
nature” that links impaired fatty acid oxidation to HI
and that provides support for the concept that a lipid
signaling pathway (14) is implicated in the control of
insulin secretion. It raises the possibility that HI might
contribute to hypoglycemia in other FAODs.
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